Antibiotic | Patients | Time for which used years median (range) |
Amikacin# | 16 (100%) | 2.3 (0.56–8.6) |
Inhaled amikacin including LAI | 16 (100%) | 2.3 (0.56–7.7) |
Intravenous amikacin | 3 (19%) | 0.16 (0.08–0.88) |
Macrolide | 15 (94%) | 7.2 (1.3–10.7) |
LAI: liposomal amikacin for inhalation. #: includes LAI in the context of a clinical trial for six patients. Of these, four patients participated in the blinded phase of this trial and their allocation is unknown. For these patients, this measure includes prescriptions for “LAI or placebo”. For all four patients, “LAI or placebo” accounted for <8% of their total amikacin exposure.